8-year follow-up of a successful outcome of massive pulmonary embolism with cardiogenic shock

Author:

Semigolovskii N. Yu.1ORCID,Mazurenko S. O.2ORCID,Shabalina M. O.2ORCID,Semigolovskii S. N.3ORCID

Affiliation:

1. Clinical Hospital No. 122 of the North- Western District Scientific and Clinical Center named after L.G. Sokolov; St Petersburg State University

2. St Petersburg State University

3. GrandMed Surgery

Abstract

Currently pulmonary embolism (PE) is already on the 3rd place in terms of the frequency of occurrence among vascular diseases, and there is a global trend towards an increase in its frequency. PE is also considered as the most common cause of preventable death in the hospital. In the countries of Europe, Asia and the USA, there is a tendency to reduce the cases of fatal PE due to the  use of  more effective conservative therapy, invasive interventions and following the  Recommendations. Since 2019, the European Guidelines for the diagnosis and treatment of PE have made the use of direct oral anticoagulants preferable in comparison with oral vitamin K antagonists.A case of massive PE in a 42-year-old patient developed in the specialized department of the hospital shortly after being transferred from the intensive care unit with verified PE of small branches (D-dimer, lung scintigraphy, Echo-cardiography) is presented. The debut of a massive PE in the form of a syncopal state with cardiogenic shock, required an urgent transfer of the patient to artificial lung ventilation, the use of vasopressors and systemic thrombolysis. During Echo-cardiography, a mobile blood clot was located in the right atrium. An emergency thrombectomy was performed from the pulmonary trunk and pulmonary arteries in conditions of artificial blood circulation, later a cava filter was installed. The features of anamnesis characteristic of PE (hormonal contraceptives), complaints (sudden shortness of breath, heaviness behind the sternum at admission) and concomitant pathology (drug-induced thyrotoxicosis) are analyzed.The  results of  the  subsequent 8-year follow-up without relapses of  PE are considered, the  feature of  which was the  use of Rivaroxaban as an anticoagulant and angiovit (B vitamins – 6, 9 and 12) for the correction of hereditary hyperhomocysteinemia. Risk factors and modern standards of treatment of massive PE in the acute period and in the long term are discussed.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference29 articles.

1. Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.J., Harjola V.P. еt al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respiratory J. 2020;41(4):543–603. https://doi.org/10.1183/13993003.01647-2019.

2. Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez D., Bounameaux H. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026.

3. Lobastov K.V. Modern approaches to determining the duration of anticoagulant therapy for venous thromboembolic complication Khirurgiya. Zhurnal im. N.I. Pirogova = Pirogov Russian Journal of Surgery. 2019;(5):94–103. (In Russ.) https://doi.org/10.17116/hirurgia201905194.

4. Konstantinides S.V., Torbicki A. Agnelli G., Danchin N., Fitzmaurice D., Galiè N. et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35:3033–3069. https://doi.org/10.1093/eurheartj/ehu283.

5. Soboleva E.V. Homocysteinemia as a target of therapeutic effect in patients with coronary heart disease. Effects of simvastatin. RMZh = RMJ. 2007;(2):58–63. (In Russ.) Available at: https://www.rmj.ru/articles/kardiologiya/Gomocisteinemiya_kak_misheny_terapevticheskogo_vozdeystviya_u_ bolynyh_ishemicheskoy_boleznyyu_serdca_Effekty_simvastatina/.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3